Horikawa Chika, Kodama Saroru, Fujihara Kazuya, Hirasawa Reiko, Yachi Yoko, Suzuki Akiko, Hanyu Osamu, Shimano Hitoshi, Sone Hirohito
Department of Health and Nutrition, University of Niigata Prefecture, Faculty of Human Life Studies, Niigata, Japan; Department of Internal Medicine, Niigata University, Faculty of Medicine, Niigata, Japan; Department of Internal Medicine, University of Tsukuba, Institute of Clinical Medicine, Ibaraki, Japan.
Department of Internal Medicine, Niigata University, Faculty of Medicine, Niigata, Japan; Department of Health Management Center, Mito Kyodo General Hospital, Ibaraki, Japan.
Diabetes Res Clin Pract. 2014 Oct;106(1):81-7. doi: 10.1016/j.diabres.2014.07.009. Epub 2014 Jul 23.
AIMS: Eradication of Helicobacter pylori (HP) is an effective approach to improve intestinal symptoms and prevent gastric cancer. However, there has been concern that the presence of diabetes reduces the effectiveness of antibiotics. We performed this meta-analysis to investigate the effect of diabetes on the risk of failing eradication in patients with diabetes. METHODS: An electronic literature search was conducted using Biosis, MEDLINE, Embase, PASCAL, and SciSearch through November 30, 2012. Selected studies had to provide data on the number of individuals who received treatment for HP infection and on the failure of HP eradication in groups with and without diabetes. Two authors independently extracted relevant data. RESULTS: Data were obtained from 8 eligible studies (693 total participants including 273 participants with diabetes). Overall, the pooled risk ratio (RR) of failing HP eradication for diabetic patients compared with non-diabetic participants was 2.19 [95%CI, 1.65-2.90] (P<0.001). Excluding the 2 studies that used a non-standard protocol for HP eradication, individuals with diabetes had a higher risk of failure of eradication compared to those without diabetes (RR=2.31 [95%CI, 1.72-3.11]). CONCLUSIONS: Current meta-analysis confirmed the higher risk of HP eradication failure in individuals with diabetes compared with those without diabetes, suggesting the necessity of prolonging treatment or developing a new regimen for HP eradication in patients with diabetes.
目的:根除幽门螺杆菌(HP)是改善肠道症状和预防胃癌的有效方法。然而,有人担心糖尿病的存在会降低抗生素的疗效。我们进行了这项荟萃分析,以研究糖尿病对糖尿病患者根除失败风险的影响。 方法:通过Biosis、MEDLINE、Embase、PASCAL和SciSearch对截至2012年11月30日的电子文献进行检索。入选研究必须提供接受HP感染治疗的个体数量以及糖尿病组和非糖尿病组HP根除失败的数据。两位作者独立提取相关数据。 结果:数据来自8项符合条件的研究(共693名参与者,其中273名糖尿病患者)。总体而言,与非糖尿病参与者相比,糖尿病患者HP根除失败的合并风险比(RR)为2.19[95%CI,1.65 - 2.90](P<0.001)。排除2项使用非标准HP根除方案的研究后,糖尿病患者根除失败的风险高于非糖尿病患者(RR = 2.31[95%CI,1.72 - 3.11])。 结论:当前的荟萃分析证实,与非糖尿病患者相比,糖尿病患者HP根除失败的风险更高,这表明有必要延长糖尿病患者HP根除的治疗时间或制定新的治疗方案。
Diabetes Res Clin Pract. 2014-10
Cochrane Database Syst Rev. 2013-12-11
World J Gastroenterol. 2016-3-28
World J Gastroenterol. 2018-6-14
Complement Ther Med. 2019-1-9
BMC Gastroenterol. 2015-10-21
World J Gastroenterol. 2024-10-21
Therap Adv Gastroenterol. 2024-9-14
Microorganisms. 2022-1-29
World J Diabetes. 2021-11-15